{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.17","value":"4.7"},{"groupId":"OG001","spread":"20.94","value":"3.9"},{"groupId":"OG002","spread":"23.20","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"433"},{"groupId":"OG001","value":"443"},{"groupId":"OG002","value":"415"}],"units":"Participants"}],"title":"Month 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.28","value":"8.5"},{"groupId":"OG001","spread":"22.95","value":"9.2"},{"groupId":"OG002","spread":"25.06","value":"6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"416"},{"groupId":"OG001","value":"414"},{"groupId":"OG002","value":"394"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.67","value":"9.8"},{"groupId":"OG001","spread":"24.84","value":"12.3"},{"groupId":"OG002","spread":"25.26","value":"8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"377"},{"groupId":"OG002","value":"350"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.90","value":"10.8"},{"groupId":"OG001","spread":"24.41","value":"12.1"},{"groupId":"OG002","spread":"26.30","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"299"},{"groupId":"OG002","value":"249"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.96","value":"12.7"},{"groupId":"OG001","spread":"24.76","value":"11.7"},{"groupId":"OG002","spread":"21.75","value":"9.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"239"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.91","value":"5.8"},{"groupId":"OG001","spread":"26.71","value":"8.8"},{"groupId":"OG002","spread":"27.13","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"254"}],"units":"Participants"}],"title":"Discontinuation Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"504"},{"groupId":"OG001","value":"508"},{"groupId":"OG002","value":"509"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future.","dispersionType":"Standard Deviation","groups":[{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.","id":"OG000","title":"Lenalidomide and Low-Dose Dexamethasone (Rd)"},{"description":"Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \\> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.","id":"OG001","title":"Lenalidomide and Dexamethasone Rd18"},{"description":"Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.","id":"OG002","title":"Melphalan + Prednisone + Thalidomide (MPT)"}],"paramType":"MEAN","populationDescription":"ITT population with available data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit","title":"Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}